stock faces challenges amid pipeline setbacks By Investing.com
Marinus (NASDAQ:) Pharmaceuticals, Inc. (NASDAQ:MRNS), a biopharmaceutical company specializing in the development of treatments for rare epilepsy disorders, has recently faced significant challenges in its clinical pipeline. Despite these setbacks, the company continues to navigate the competitive landscape of rare seizure disorders, leveraging its commercial success with ZTALMY while exploring strategic alternatives for future growth.
Company Overview
Marinus Pharmaceuticals focuses on developing and commercializing innovative therapies for patients suffering from rare seizure disorders. The company’s lead product, ZTALMY (ganaxolone), is approved for the treatment of seizures associated with CDKL5 Deficiency Disorder (CDD), a rare…
